Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third‐line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study
Abstract
Funding information National Center for Advancing Translational Sciences, Grant/Award Number: UCLA CTSI UL1TR000124; National Institute of General Medical Sciences, Grant/Award Number: SC3GM113767; National Institute on Minority Health and Health Disparities, Grant/Award Number: U54 MD007598 Highlights • The anti-inflammatory agent, hydroxychloroquine, improved glycemic control in type 2 diabetes patients when used as a third-line agent added to metformin and a sulfonylurea. • In comparison to pioglitazone, hydroxychloroquine lowered hemoglobin A1c levels less effectively and did not improve insulin sensitivity, but also did not cause any weight gain, hypoglycemia, or pedal edema. • In this small, proof-of-concept study, hydroxychloroquine was well tolerated and may be an alternative treatment choice in combination with other agents.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.